{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T01:34:23Z","timestamp":1769823263738,"version":"3.49.0"},"reference-count":30,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100010476","name":"Tata Memorial Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010476","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinical-breast-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Breast Cancer"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clbc.2020.03.012","type":"journal-article","created":{"date-parts":[[2020,4,6]],"date-time":"2020-04-06T11:26:02Z","timestamp":1586172362000},"page":"382-389","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":11,"title":["Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1404-7347","authenticated-orcid":false,"given":"Akash P.","family":"Sali","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nishtha","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anuj","family":"Verma","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9413-4813","authenticated-orcid":false,"given":"Amruta","family":"Beke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanuja","family":"Shet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Asawari","family":"Patil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Trupti","family":"Pai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5481-7292","authenticated-orcid":false,"given":"Nita","family":"Nair","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vani","family":"Parmar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sudeep","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rohini","family":"Hawaldar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sangeeta B.","family":"Desai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clbc.2020.03.012_bib1","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1093\/annonc\/mdi352","article-title":"Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?","volume":"16","author":"Colozza","year":"2005","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib2","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1038\/bjc.1998.515","article-title":"MIB-1 labelling index is an independent prognostic marker in primary breast cancer","volume":"78","author":"Jansen","year":"1998","journal-title":"Br J Cancer"},{"key":"10.1016\/j.clbc.2020.03.012_bib3","doi-asserted-by":"crossref","first-page":"10869","DOI":"10.1073\/pnas.191367098","article-title":"Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications","volume":"98","author":"Sorlie","year":"2001","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.clbc.2020.03.012_bib4","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/1755-8794-5-44","article-title":"PAM50 breast cancer subtyping by RT-qPCR and concordance with standard clinical molecular markers","volume":"5","author":"Bastien","year":"2012","journal-title":"BMC Med Genomics"},{"key":"10.1016\/j.clbc.2020.03.012_bib5","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/nature11412","article-title":"Comprehensive molecular portraits of human breast tumours","volume":"490","author":"Koboldt","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.clbc.2020.03.012_bib6","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1111\/j.1349-7006.2012.02319.x","article-title":"Immunohistochemical Ki67 labeling index has similar proliferation predictive power to various gene signatures in breast cancer","volume":"103","author":"Niikura","year":"2012","journal-title":"Cancer Sci"},{"key":"10.1016\/j.clbc.2020.03.012_bib7","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1097\/PDM.0b013e31818d107b","article-title":"Molecular classification of breast carcinomas by immunohistochemical analysis: are we ready?","volume":"18","author":"Tang","year":"2009","journal-title":"Diagn Mol Pathol"},{"key":"10.1016\/j.clbc.2020.03.012_bib8","doi-asserted-by":"crossref","first-page":"2206","DOI":"10.1093\/annonc\/mdt303","article-title":"Personalizing the treatment of women\u00a0with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2013","volume":"24","author":"Goldhirsch","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib9","doi-asserted-by":"crossref","first-page":"149","DOI":"10.4048\/jbc.2015.18.2.149","article-title":"Differences in clinical outcomes between luminal A and B type breast cancers according to the St Gallen consensus, 2013","volume":"18","author":"Ahn","year":"2015","journal-title":"J\u00a0Breast Cancer"},{"key":"10.1016\/j.clbc.2020.03.012_bib10","doi-asserted-by":"crossref","first-page":"1656","DOI":"10.1093\/jnci\/djr393","article-title":"Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer Working Group","volume":"103","author":"Dowsett","year":"2011","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.03.012_bib11","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1200\/JOP.777003","article-title":"American Society of Clinical Oncology\/College of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer","volume":"6","author":"Hammond","year":"2010","journal-title":"J\u00a0Oncol Pract"},{"key":"10.1016\/j.clbc.2020.03.012_bib12","doi-asserted-by":"crossref","first-page":"3997","DOI":"10.1200\/JCO.2013.50.9984","article-title":"Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology\/College of American Pathologists clinical practice guideline update","volume":"31","author":"Wolff","year":"2013","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib13","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1038\/modpathol.2013.153","article-title":"Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information","volume":"27","author":"Feeley","year":"2014","journal-title":"Mod Pathol"},{"key":"10.1016\/j.clbc.2020.03.012_bib14","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1093\/annonc\/mdn675","article-title":"Breast cancer classification according to immunohistochemical markers: clinicopathologic features and short-term survival analysis in a population-based study from the South of Switzerland","volume":"20","author":"Spitale","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib15","doi-asserted-by":"crossref","first-page":"496","DOI":"10.20892\/j.issn.2095-3941.2016.0066","article-title":"Ki-67 as a prognostic marker according to breast cancer molecular subtype","volume":"13","author":"Soliman","year":"2016","journal-title":"Cancer Biol Med"},{"key":"10.1016\/j.clbc.2020.03.012_bib16","doi-asserted-by":"crossref","first-page":"R3","DOI":"10.1186\/bcr3084","article-title":"Prognostic value of proliferation assay in the luminal, HER2-positive, and triple-negative biologic classes of breast cancer","volume":"14","author":"Aleskandarany","year":"2012","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.clbc.2020.03.012_bib17","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1007\/s10549-013-2560-8","article-title":"Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry","volume":"139","author":"Inwald","year":"2013","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.03.012_bib18","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1093\/annonc\/mdp322","article-title":"Thresholds for therapies: highlights of the St Gallen International Expert Consensus on the primary therapy of early breast cancer 2009","volume":"20","author":"Goldhirsch","year":"2009","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib19","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1093\/annonc\/mdr304","article-title":"Strategies for subtypes\u2014dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer, 2011","volume":"22","author":"Goldhirsch","year":"2011","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib20","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1093\/jnci\/djp082","article-title":"Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer","volume":"101","author":"Cheang","year":"2009","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.clbc.2020.03.012_bib21","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1159\/000430488","article-title":"St Gallen\/Vienna 2015: a brief summary of the consensus discussion","volume":"10","author":"Gnant","year":"2015","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2020.03.012_bib22","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1159\/000475698","article-title":"St Gallen\/Vienna 2017: a brief summary of the consensus discussion about escalation and de-escalation of primary breast cancer treatment","volume":"12","author":"Gnant","year":"2017","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2020.03.012_bib23","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1159\/000499931","article-title":"St Gallen\/Vienna 2019: a brief summary of the consensus discussion on the optimal primary breast cancer treatment","volume":"14","author":"Balic","year":"2019","journal-title":"Breast Care"},{"key":"10.1016\/j.clbc.2020.03.012_bib24","doi-asserted-by":"crossref","first-page":"86","DOI":"10.4103\/2278-330X.187561","article-title":"Breast cancer: an overview of published Indian data","volume":"5","author":"Rangarajan","year":"2016","journal-title":"South Asian J Cancer"},{"key":"10.1016\/j.clbc.2020.03.012_bib25","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1007\/s12282-013-0455-5","article-title":"Ki-67 evaluation at the hottest spot predicts clinical outcome of patients with hormone receptor\u2013positive\/HER2-negative breast cancer treated with adjuvant tamoxifen monotherapy","volume":"22","author":"Honma","year":"2015","journal-title":"Breast Cancer"},{"key":"10.1016\/j.clbc.2020.03.012_bib26","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.anndiagpath.2015.05.002","article-title":"A\u00a0standardized method for quantifying proliferation by Ki-67 and cyclin A immunohistochemistry in breast cancer","volume":"19","author":"Mu","year":"2015","journal-title":"Ann Diagn Pathol"},{"key":"10.1016\/j.clbc.2020.03.012_bib27","doi-asserted-by":"crossref","first-page":"e0172031","DOI":"10.1371\/journal.pone.0172031","article-title":"A\u00a0comparison of Ki-67 counting methods in luminal breast cancer: the average method vs the hot spot method","volume":"12","author":"Jang","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.clbc.2020.03.012_bib28","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10549-016-3817-9","article-title":"Optimal Ki67 cut-off for luminal breast cancer prognostic evaluation: a large case series study with a long-term follow-up","volume":"157","author":"Bustreo","year":"2016","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.clbc.2020.03.012_bib29","doi-asserted-by":"crossref","first-page":"107","DOI":"10.4137\/CMO.S18006","article-title":"Difference between luminal A and luminal B subtypes according to Ki-67, tumor size, and progesterone receptor negativity providing prognostic information","volume":"8","author":"Inic","year":"2014","journal-title":"Clin Med Insights Oncol"},{"key":"10.1016\/j.clbc.2020.03.012_bib30","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.2012.43.4134","article-title":"Prognostic significance of progesterone receptor\u2013positive tumor cells within immunohistochemically defined luminal A breast cancer","volume":"31","author":"Prat","year":"2013","journal-title":"J\u00a0Clin Oncol"}],"container-title":["Clinical Breast Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300689?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1526820920300689?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T21:20:17Z","timestamp":1761513617000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1526820920300689"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":30,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S1526820920300689"],"URL":"https:\/\/doi.org\/10.1016\/j.clbc.2020.03.012","relation":{},"ISSN":["1526-8209"],"issn-type":[{"value":"1526-8209","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Identification of Luminal Subtypes of Breast Carcinoma Using Surrogate Immunohistochemical Markers and Ascertaining Their Prognostic Relevance","name":"articletitle","label":"Article Title"},{"value":"Clinical Breast Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clbc.2020.03.012","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}